DAT polymorphism and diverse clinical manifestations in methamphetamine abusers

Hsing Cheng Liu, Shih Ku Lin, Shih Kai Liu, Su Lien Chen, Chaur Jong Hu, Jan Gowth Chang, Sy Jye Leu

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The clinical outcome for methamphetamine (MAP) abusers is variable. MAP exerts its biological activity through rapid conversion to amphetamine (AP) and MAP itself. The dopamine transporter (DAT) is the main modulator of MAP/ AP-induced dopamine release and dopamine neurotoxicity, and is also the major regulator of dopamine level in the brain. We tested for an association between a DAT-gene polymorphism and clinical variations in MAP abusers. A total of 146 MAP abusers were enrolled in the study and classified into three clinically distinct groups: MAP dependence (n=30), MAP psychosis (n=88) and chronic MAP psychosis (n=28). Patients with schizophrenic (n=79) and healthy controls (n=72) were also recruited for the study. The 40 base pair variable number tandem repeat polymorphism in the 3′-untranslated region of the DAT was the focus of the investigation. The subjects were all Chinese residents of Taiwan. The respective allelic frequencies for DAT repeats 11, 10 and 9 were 0.067, 0.833 and 0.083 for the MAP-dependence group, 0.006, 0.864 and 0.119 for the MAP psychosis group, 0.018, 0.893 and 0.089 for the chronic MAP psychosis group, 0.019, 0.911 and 0.07 for the schizophrenic controls, and 0.021, 0.889 and 0.083 for the healthy controls. No significant associations were demonstrated between this DAT polymorphism in genotype and allele frequency and the clinical outcome of MAP abusers. The biological relevance of the variable number tandem repeat polymorphism in the 3′-untranslated region of DAT in MAP abusers was not demonstrated in this study.

Original languageEnglish
Pages (from-to)33-37
Number of pages5
JournalPsychiatric Genetics
Volume14
Issue number1
DOIs
Publication statusPublished - Mar 2004
Externally publishedYes

Fingerprint

Dopamine Plasma Membrane Transport Proteins
Methamphetamine
Psychotic Disorders
Dopamine
Minisatellite Repeats
3' Untranslated Regions
Amphetamine
Taiwan
Gene Frequency
Base Pairing

Keywords

  • Dopamine
  • Dopamine transporter
  • Methamphetamine
  • Schizophrenia
  • Variable number tandem repeat polymorphism

ASJC Scopus subject areas

  • Genetics(clinical)
  • Psychiatry and Mental health
  • Genetics
  • Neuroscience(all)

Cite this

DAT polymorphism and diverse clinical manifestations in methamphetamine abusers. / Liu, Hsing Cheng; Lin, Shih Ku; Liu, Shih Kai; Chen, Su Lien; Hu, Chaur Jong; Chang, Jan Gowth; Leu, Sy Jye.

In: Psychiatric Genetics, Vol. 14, No. 1, 03.2004, p. 33-37.

Research output: Contribution to journalArticle

Liu, Hsing Cheng ; Lin, Shih Ku ; Liu, Shih Kai ; Chen, Su Lien ; Hu, Chaur Jong ; Chang, Jan Gowth ; Leu, Sy Jye. / DAT polymorphism and diverse clinical manifestations in methamphetamine abusers. In: Psychiatric Genetics. 2004 ; Vol. 14, No. 1. pp. 33-37.
@article{85e07ec3af424480b9677c991f63ab85,
title = "DAT polymorphism and diverse clinical manifestations in methamphetamine abusers",
abstract = "The clinical outcome for methamphetamine (MAP) abusers is variable. MAP exerts its biological activity through rapid conversion to amphetamine (AP) and MAP itself. The dopamine transporter (DAT) is the main modulator of MAP/ AP-induced dopamine release and dopamine neurotoxicity, and is also the major regulator of dopamine level in the brain. We tested for an association between a DAT-gene polymorphism and clinical variations in MAP abusers. A total of 146 MAP abusers were enrolled in the study and classified into three clinically distinct groups: MAP dependence (n=30), MAP psychosis (n=88) and chronic MAP psychosis (n=28). Patients with schizophrenic (n=79) and healthy controls (n=72) were also recruited for the study. The 40 base pair variable number tandem repeat polymorphism in the 3′-untranslated region of the DAT was the focus of the investigation. The subjects were all Chinese residents of Taiwan. The respective allelic frequencies for DAT repeats 11, 10 and 9 were 0.067, 0.833 and 0.083 for the MAP-dependence group, 0.006, 0.864 and 0.119 for the MAP psychosis group, 0.018, 0.893 and 0.089 for the chronic MAP psychosis group, 0.019, 0.911 and 0.07 for the schizophrenic controls, and 0.021, 0.889 and 0.083 for the healthy controls. No significant associations were demonstrated between this DAT polymorphism in genotype and allele frequency and the clinical outcome of MAP abusers. The biological relevance of the variable number tandem repeat polymorphism in the 3′-untranslated region of DAT in MAP abusers was not demonstrated in this study.",
keywords = "Dopamine, Dopamine transporter, Methamphetamine, Schizophrenia, Variable number tandem repeat polymorphism",
author = "Liu, {Hsing Cheng} and Lin, {Shih Ku} and Liu, {Shih Kai} and Chen, {Su Lien} and Hu, {Chaur Jong} and Chang, {Jan Gowth} and Leu, {Sy Jye}",
year = "2004",
month = "3",
doi = "10.1097/00041444-200403000-00005",
language = "English",
volume = "14",
pages = "33--37",
journal = "Psychiatric Genetics",
issn = "0955-8829",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - DAT polymorphism and diverse clinical manifestations in methamphetamine abusers

AU - Liu, Hsing Cheng

AU - Lin, Shih Ku

AU - Liu, Shih Kai

AU - Chen, Su Lien

AU - Hu, Chaur Jong

AU - Chang, Jan Gowth

AU - Leu, Sy Jye

PY - 2004/3

Y1 - 2004/3

N2 - The clinical outcome for methamphetamine (MAP) abusers is variable. MAP exerts its biological activity through rapid conversion to amphetamine (AP) and MAP itself. The dopamine transporter (DAT) is the main modulator of MAP/ AP-induced dopamine release and dopamine neurotoxicity, and is also the major regulator of dopamine level in the brain. We tested for an association between a DAT-gene polymorphism and clinical variations in MAP abusers. A total of 146 MAP abusers were enrolled in the study and classified into three clinically distinct groups: MAP dependence (n=30), MAP psychosis (n=88) and chronic MAP psychosis (n=28). Patients with schizophrenic (n=79) and healthy controls (n=72) were also recruited for the study. The 40 base pair variable number tandem repeat polymorphism in the 3′-untranslated region of the DAT was the focus of the investigation. The subjects were all Chinese residents of Taiwan. The respective allelic frequencies for DAT repeats 11, 10 and 9 were 0.067, 0.833 and 0.083 for the MAP-dependence group, 0.006, 0.864 and 0.119 for the MAP psychosis group, 0.018, 0.893 and 0.089 for the chronic MAP psychosis group, 0.019, 0.911 and 0.07 for the schizophrenic controls, and 0.021, 0.889 and 0.083 for the healthy controls. No significant associations were demonstrated between this DAT polymorphism in genotype and allele frequency and the clinical outcome of MAP abusers. The biological relevance of the variable number tandem repeat polymorphism in the 3′-untranslated region of DAT in MAP abusers was not demonstrated in this study.

AB - The clinical outcome for methamphetamine (MAP) abusers is variable. MAP exerts its biological activity through rapid conversion to amphetamine (AP) and MAP itself. The dopamine transporter (DAT) is the main modulator of MAP/ AP-induced dopamine release and dopamine neurotoxicity, and is also the major regulator of dopamine level in the brain. We tested for an association between a DAT-gene polymorphism and clinical variations in MAP abusers. A total of 146 MAP abusers were enrolled in the study and classified into three clinically distinct groups: MAP dependence (n=30), MAP psychosis (n=88) and chronic MAP psychosis (n=28). Patients with schizophrenic (n=79) and healthy controls (n=72) were also recruited for the study. The 40 base pair variable number tandem repeat polymorphism in the 3′-untranslated region of the DAT was the focus of the investigation. The subjects were all Chinese residents of Taiwan. The respective allelic frequencies for DAT repeats 11, 10 and 9 were 0.067, 0.833 and 0.083 for the MAP-dependence group, 0.006, 0.864 and 0.119 for the MAP psychosis group, 0.018, 0.893 and 0.089 for the chronic MAP psychosis group, 0.019, 0.911 and 0.07 for the schizophrenic controls, and 0.021, 0.889 and 0.083 for the healthy controls. No significant associations were demonstrated between this DAT polymorphism in genotype and allele frequency and the clinical outcome of MAP abusers. The biological relevance of the variable number tandem repeat polymorphism in the 3′-untranslated region of DAT in MAP abusers was not demonstrated in this study.

KW - Dopamine

KW - Dopamine transporter

KW - Methamphetamine

KW - Schizophrenia

KW - Variable number tandem repeat polymorphism

UR - http://www.scopus.com/inward/record.url?scp=1642327100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642327100&partnerID=8YFLogxK

U2 - 10.1097/00041444-200403000-00005

DO - 10.1097/00041444-200403000-00005

M3 - Article

VL - 14

SP - 33

EP - 37

JO - Psychiatric Genetics

JF - Psychiatric Genetics

SN - 0955-8829

IS - 1

ER -